Effect of Perioperative Sivelstat Administration for Liver Resection
NCT ID: NCT00738348
Last Updated: 2012-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2007-04-30
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pringle Time Exceeding 120 Min in Liver Resection
NCT01237002
Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection
NCT00730743
Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy
NCT06594289
A Trial to Compare Pringle Maneuver With Either Infrahepatic Inferior Vena Cava Clamping or Low Central Venous Pressure
NCT01355887
Ischemic Preconditioning at a Distance in Liver Surgery
NCT04181502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
sivelstat
sivelstat sodiumhydrate
1
250mL of 5% glucose was injected though the vein at 10mL per an hour
glucose
glucose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sivelstat
sivelstat sodiumhydrate
glucose
glucose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kochi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Takehiro Okabayashi
University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Takehiro Okabayashi, MD, PhD
Role: STUDY_DIRECTOR
Kochi Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kochi Medical School
Kohasu-Okocho, Nankoku, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Kochi University
Identifier Type: -
Identifier Source: secondary_id
ESAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.